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Abstract
The stability of an Abl kinase substrate peptide in a cytosolic lysate and in single cells was
characterized. In the cytosolic lysate, the starting peptide was metabolized at an average initial rate
of 1.7 ± 0.3 zmol pg−;1 s−;1 with a t1/2 of 1.3 min. Five different fragments formed over time;
however, a dominant cleavage site was identified. Multiple rational design cycles were utilized to
develop a lead peptide with a phenylalanine and alanine replaced by an (N-methyl)phenylalanine
and isoleucine, respectively, to attain cytosolic peptidase resistance while maintaining Abl
substrate efficacy. This lead peptide possessed a 15-fold greater lifetime in the cytosolic lysate
while attaining a 7-fold improvement in kcat as an Abl kinase substrate compared to the starting
peptide. However, when loaded into single cells, the starting peptide and lead peptide possessed
nearly identical degradation rates and an altered pattern of fragmentation relative to that in cell
lysates. Preferential accumulation of a fragment with cleavage at an Ala-Ala bond in single cells
suggested that dissimilar peptidases act on the peptides in the lysate versus single cells. A design
strategy for peptide stabilization, analogous to that demonstrated for the lysate, should be effective
for stabilization in single cells.
Introduction
Synthetic peptides have found widespread use in biomedical research particularly as
substrates and inhibitors of kinases and peptidases. The chemistry of solid-phase peptide
synthesis is well-defined, permitting relatively straightforward construction of large
quantities of peptides comprised of native and non-native amino acids. Peptides have a long
shelf life and are readily derivatized with labels such as fluorophores and targeting elements
(e.g. biotin). Peptides are an attractive alternative to proteins in a variety of applications (e.g.
enzyme assays) due to their chemical simplicity and ease of handling. Furthermore, the
substrate preference of many protein kinases is largely determined by the amino acid
sequence surrounding the phosphoryl-accepting residue. Consequently, consensus peptide
sequences have been defined for large numbers of these enzymes.1–4 In many cases, these
short peptide sequences mimic the kinetic properties of the native protein substrates for the
enzyme. For kinases, replacement of the residue that undergoes phosphorylation (serine,
threonine, or tyrosine) with a non-phosphorylatable analogue (alanine or phenylalanine)
often yields a peptide with excellent inhibitory properties for the targeted kinase.5, 6
Modifications of a peptide substrate with non-native residues can lead to effective and stable
inhibitors when the inhibitor peptide binds tightly to the substrate binding domain of the
kinase and prevents docking of the target substrate.5, 7 For these reasons, a wide array of
substrate and inhibitor peptides are commercially available to manipulate or monitor a
plethora of kinase activities in in vitro systems.
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In addition to their use in assays with purified kinases, peptides are often used to assay
kinase activity in cell lysates and also increasingly in intact cells.8–15 Cell lysates offer a
native enzyme in an environment which retains many of the co-factors and other regulatory
elements of the cell. Cell lysates can be prepared in large volumes to meet the sensitivity
needs of almost any detection strategy. Manipulation of the reaction environment by
addition or removal of modifiers or inhibitors is also relatively trivial in a cell lysate
compared to intact cells. However, lysates do not recapitulate the environment of an intact
cell in a variety of ways. For example, the contents of a cell lysate are diluted and
intermixed when intracellular compartments are fragmented during lysis, resulting in a loss
of protein compartmentalization as well as normal spatial relationships found in intact cells.
Additionally, the heterogeneity of single cell populations has been well documented16, 17
and cell lysates eliminate this heterogeneity when samples are pooled. For these reasons,
intact cells are also used as an assay format in which peptides act as inhibitors or substrates
for enzymes.18–20 The low molecular weight of peptides offers the advantage of efficient
loading into cells relative to intact proteins.21 The loading of substrate peptides into cells
followed by lysis and separation of substrate and product by electrophoresis has been
performed to track a variety of enzymatic reactions including those of kinases, acyl
transferases, and proteases.22–24 This strategy offers direct quantification of the substrate
and product quantities as well as the identification of the products of competing reactions
with zeptomole detection limits.
Despite their benefits as substrates and inhibitors in biomedical research, the use of peptides
in the presence of cellular constituents is plagued by unwanted and rapid proteolysis. Exo-
and endo-peptidases are an integral part of the protein recycling and antigen processing
machinery of cells and ensure that most peptides are rapidly hydrolyzed to their amino acid
constituents.25 While peptidase inhibitors can be used to slow these reactions, they are
generally insufficient to eliminate peptide hydrolysis, are often not specific to a single
protease, and have significant other off-target effects. Furthermore, many peptidase
inhibitors are poorly soluble in aqueous solutions necessitating the use of organic solvents
that may interfere with cellular reactions. To prevent peptide bond hydrolysis, a number of
alternative strategies have been utilized to impart stability to peptides. Peptide cyclization
reduces degradation by creating a fixed secondary structure preventing protease access to
the peptide bond.26–29 Although circularized peptides are excellent at resisting peptidase
actions, peptide cyclization can be difficult and is often of low yield due to competing
intermolecular reactions. More importantly, cyclization often reduces or eliminates the
ability of kinases to phosphorylate the peptide. Another method frequently utilized to impart
stability to peptides is the addition of a polyethylene glycol moiety (PEGylation); shorter
PEG chains (average molecular weight of approximately 6,000 Da) attached to peptides
show better affinity for the targeted enzyme yet less ability to resist degradation than
PEGylated peptides with average molecular weights near 25,000 Da.30–32 The addition of a
PEG group greatly increases substrate molecular weight and diminishes the chemical
differences of the substrate and product, making detection and quantification of the substrate
and product challenging. The polydispersity of molecular weights in PEG formulations also
yields unacceptably broad electrophoretic peaks. Introduction of non-native residues into
peptides, which can be achieved with standard solid phase synthesis strategies, has been
shown to block unwanted proteolytic reactions. This strategy has been particularly
successful in stabilizing inhibitor peptides.30, 33–38 Extensive libraries of non-native amino
acids provide numerous possibilities for the construction of selective inhibitors or substrates,
as demonstrated by Lee et al. in 2004.14 However, design of peptides that act as substrates
for specific enzymes yet are peptidase resistant has been challenging.
A strategy was developed to rationally design a kinase-substrate peptide with increased
stability in cell lysates and intact cells. A consensus substrate sequence was selected for Abl
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kinase and used as the starting point for the design modifications. Abl kinase was chosen
because of its role in chronic myelogenous leukemia (CML), where a constitutively active
Abl enzyme results from the fusion of the Bcr to Abl protein in a majority of patients with
CML.39 The average rate and locations of lysate-induced cleavage sites in an Abl peptide
substrate were identified by capillary electrophoresis. The starting peptide was then
modified by replacement of residues adjacent to the identified cleavage site with non-native
amino acids and then re-evaluated for peptidase resistance in the cell lysate. The modified
peptides were also evaluated for Abl substrate suitability. Multiple cycles of peptide
modification and assessment of protease resistance and kinase substrate efficacy generated a
final modified peptide that was characterized in a cell lysate. The substrate was also assessed
for phosphorylation by Abl relative to the starting sequence. Proteolytic sensitivity of both




Peptide synthesis reagents were purchased from Aldrich or Fisher except for the following:
2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate
(HCTU), 1-(Mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole (MSNT), 9-
Fluorenylmethoxycarbonyl (Fmoc) amino acids, 5-carboxyfluorescien (5-FAM) and resins
were received from ChemPep or NovaBiochem; N-Hydroxybenzotriazole (HOBt) was
obtained from AnaSpec; and Fmoc-3-(2-Naphthyl)-L-Alanine was purchased from Peptides
International. All other chemicals used in the assays were procured from Fisher or Sigma
except for the following: Active Abl-1 enzyme was purchased from Invitrogen; bovine
serum albumin (BSA) was received from Calbiochem; Roswell Park Memorial Institute
Media (RPMI-1640) and Dulbecco’s Modified Eagle’s Medium (DMEM) were obtained
from Cellgro; Penicillin/streptomycin was procured from Gibco; and fetal bovine serum
(FBS) was purchased from Atlanta Biologicals.
Peptide synthesis and preparation
Full-length substrate peptides with an amidated C terminus were synthesized via standard
Fmoc peptide synthesis (Prelude Peptide Synthesizer, Protein Technologies, Tucson, AZ)
utilizing TGR resin. Coupling was performed with two 5 min incubations in
dimethylformamide (DMF) with 5 equivalents (eq) amino acid, 5 eq HCTU, and 10 eq N,N-
Diisopropylethylamine (DIPEA). Fmoc deprotection was achieved with two 2.5 min
incubations with 20% piperidine in DMF. The free N-terminus was reacted with 5 eq 5-
FAM, 5 eq diisopropylcarbodiimide (DIC), and 5 eq HOBt in DMF overnight, then treated
with 30% piperidine in DMF for 30 min. The peptide was cleaved with trifluoroacetic
acid:water:triisopropylsilane (TFA:H2O:TIS) in a ratio of 95:2.5:2.5, precipitated with ether,
and dried in air. Peptide purity was assessed with HPLC-MS and further purification via
HPLC was performed if needed. Peptides were dissolved in Tris buffer, pH 7.5, aliquoted,
and stored at −80 °C.
In some instances, amino acids were coupled overnight in N-Methyl-2-pyrrolidone (NMP)
with 5 eq amino acid, 5 eq bromo-tris-pyrrolidino phosphonium hexafluorophosphate
(PyBrop), and 10 eq DIPEA. Capping with acetic anhydride was performed if necessary and
product formation was assessed using HPLC-MS.
Peptide fragment standards with a free carboxylic acid at the peptide C terminus were
synthesized using either a Wang or 2-Chlorotrityl resin. When using the Wang resin, 10 eq
of the first Fmoc amino acid in CH2Cl2 was reacted with 7.5 eq 1-methylimidazole and 10
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eq MSNT for 15 minutes in a dry glass vial on a shaker. The reaction mixture was
transferred to another dry glass vial containing the Wang resin and incubated for 1 h. For the
2-Chlorotrityl resin, 1 eq of the first Fmoc amino acid and 4 eq DIPEA in dry CH2Cl2 was
reacted with the 2-Chlorotrityl resin for 2 h in a dry glass vial on a shaker. The remaining
amino acids were attached as described for the amidated peptides above.
Cell culture
Baf/BCR-ABL cells are a mouse B-cell lymphoma line that was stably transfected with and
overexpress Bcr-Abl.43 HeLa cells were obtained from the American Type Culture
Collection. Baf/BCR-ABL cells were cultured in RPMI-1640 medium supplemented with
10% FBS, penicillin (100 units/mL) and streptomycin (100 μg/mL). HeLa cells were
cultured in DMEM medium supplemented with 10% FBS, penicillin (100 units/mL) and
streptomycin (100 μg/mL). All cells were maintained in a humidified atmosphere of 37 °C
in 5% CO2. HeLa cells used for single cell-CE experiments were plated the day before onto
custom chambers, prepared by using poly(dimethyl siloxane) (PDMS, Sylgard 184) to glue a
silicon O-ring (McMaster-Carr) to a #1 glass coverslip (Fisher). A dilute cell suspension was
added to 500 μL of DMEM media in the chamber and the chambers were placed in the
humidified incubator until use in the experiments.
Measurement of peptide degradation in a cell lysate
A Baf/BCR-ABL cell pellet was washed with and resuspended in phosphate buffered saline
(PBS; 137 mM NaCl, 10 mM Na2HPO4, 27 mM KCl, 1.75 mM KH2PO4, pH 7.4). The cells
were submerged in liquid nitrogen for 1 min and rapidly thawed at 37 °C for a total of three
cycles. The mixture was centrifuged at 14,000 x g for 5 min at 4 °C. The supernatant was
transferred to a clean centrifuge tube and maintained on ice until use in the assay. Total
protein concentration in the supernatant was measured using fluorescamine.42 Briefly,
fluorescamine (10 μL, 3 mg/mL in acetone) was added to a cell lysate (30 μL) and
incubated for 5 min at 25 °C. Fluorescence was measured with a fluorescence plate reader
(SpectraMax M5, Molecular Devices, Sunnyvale, CA) with an excitation of 390 nm
(bandwidth of 9 nm) and emission of 475 nm (bandwidth of 15 nm).
Assay of peptide degradation was performed by mixing peptide (1 μM) with the Baf/BCR-
ABL cell lysate (3 mg/mL total cell protein) and incubating at 37 °C. Aliquots were
removed from the reaction mixture at various time intervals. The reactions were stopped by
adding HCl to a final concentration of 100 mM. A 0 min timepoint was prepared by adding
the HCl to the lysate prior to addition of the substrate peptide. Reaction mixtures were then
separated by capillary electrophoresis and detected by LIF. Peptide fragments were
identified by adding standards (250 nM) to the HCl-terminated aliquots and comparing the
electropherograms with and without the added standard. The average initial degradation and
fragmentation rates were calculated using the first two time points by monitoring the change
in peptide amount divided by the change in time per amount cytosolic protein. The units are
defined as zmol of peptide per pg of cytosolic protein per s, or zmol pg−1 s−1.
in vitro kinase assay
Protein kinase assays were performed at 30 °C in assay buffer [50 mM Tris (pH 7.4), 5 mM
MgCl2, 1 mM MnCl2, 2 mM DTT, 1 mM ATP] with Abl-1 kinase (12 nM) and substrate (29
μM). Aliquots were then removed from the reaction mixture at varying times. The reactions
were stopped by heating at 90 °C for 4 min. Additionally, a negative control with no ATP
was simultaneously assayed and sampled. The amount of peptide phosphorylation was
measured using capillary electrophoresis coupled with laser-induced fluorescence (LIF) to
separate the substrates and products and quantify peak areas. The samples with and without
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ATP were compared to identify the phosphorylated product and the non-phosphorylated
precursor (Supplementary Figure S1).
Measurement of kinetic parameters
Protein kinase assays were performed as described in the in vitro kinase assay section with
the following exceptions: substrate concentration ranged from 10 to 100 μM; Abl-1
(Invitrogen, Carlsbad, CA) enzyme concentration was 12 nM for QW-III-67B and 6 nM for
QW-V-48B. The immobilized metal ion affinity-based fluorescent polarization (IMAP)
assay (Molecular Devices Corp., Sunnyvale, CA) was used to measure the amount of
phosphorylated peptide in reaction mixtures (http://www.moleculardevices.com/pages/
reagents/imap.html). A calibration curve was constructed by measuring the anisotropy of
solutions with known ratios of phosphorylated to non-phosphorylated peptide. The standard
with 100% phosphorylated peptide was prepared using Abl-1 kinase and the percentage
phosphorylation was verified with capillary electrophoresis. Anisotropy was measured using
a fluorescence plate reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) with an
excitation of 485 nm (bandwidth of 9 nm) and emission of 525 nm (bandwidth of 15 nm).
Samples were diluted to the working concentration of 100 nM for the IMAP assay with a
buffer containing 10 mM Tris-HCl (pH 7.2), 10 mM MgCl2, and 0.01% Tween-20.
Capillary electrophoresis
Laser-induced fluorescence (LIF, 488 nm) was used for peptide detection during capillary
electrophoresis (ProteomeLab PA800, Beckman Coulter, Fullerton, CA). Fused-silica
capillaries [50 μm inner diameter, 360 μm outer diameter, (Polymicro Technologies,
Phoenix, AZ)] had a total length of 30 cm with an effective length of 20 cm. Capillaries
were conditioned prior to use with 0.1 M NaOH for 12 h, H2O for 1 h, 0.1 M HCl for 6 h,
and H2O again for 12 h. After each sample, the capillary was sequentially rinsed with 1 M
NaOH, H2O, and buffer for 2 min by applying a pressure of 20 psi to the capillary inlet. A
sample plug was hydrodynamically loaded into the capillary by applying 0.5 psi to the inlet
for 5 s. Electrophoresis was initiated by application of a negative voltage to the outlet. For
the assays employing a cell lysate, the electrophoretic buffer was 100 mM Tris and 100 mM
Tricine, pH 8.1 and the field strength was 500 V/cm. For the in vitro kinase assay samples,
the electrophoretic buffer was 100 mM Tris, 100 mM Tricine and 5 mM SDS, pH 8.1 and
field strength was 600 V/cm. The data was analyzed using commercial software (32 Karat,
version 8.0, Beckman Coulter, Fullerton, CA).
Single cell capillary electrophoresis
Single cell capillary electrophoresis was performed using a custom-made CE system with
LIF detection, as described previously.40 Fused-silica capillaries [30 μm inner diameter, 360
μm outer diameter, (Polymicro Technologies, Phoenix, AZ)] with a total length of 38 cm
and an effective length of 21.5 cm were conditioned as described above. A negative voltage
of 14 kV was applied to the outlet reservoir while the inlet reservoir was held at ground. The
electrophoretic buffer was 100 mM Tris and 100 mM Tricine, pH 8.1. Cells were perfused
with extracellular buffer (ECB; 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and
10 mM HEPES, pH 7.4, 25 °C) during experiments, with the flow turned off immediately
prior to cell lysis and loading into the capillary. Laser-based cell lysis was achieved with a
focused Nd:YAG laser as previously described.41 To identify peptide fragments formed in
cells, standards of peptide fragments (100 nM) were hydrodynamically loaded into the
capillary immediately following loading of a single HeLa cell into the capillary. The HeLa
cell was not loaded with peptide prior to loading into the capillary. The lysed HeLa cell
provided a milieu for the subsequently loaded standards similar to that for peptide obtained
from a lysed cell. To calibrate the amount of peptide on the electropherograms, a known
concentration of a standard of each intact peptide was hydrodynamically loaded into the
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capillary, electrophoresed, and the area under the peak calculated. Poiseuille’s equation was
utilized to estimate the amount of peptide injected.22 Data was collected with custom
software (LabVIEW 9.0.1, National Instruments, Austin, TX) and analyzed utilizing Origin
software (version 7.5, OriginLab Corporation, Northampton, MA).
Results and Discussion
Selection of the starting peptide
The starting peptide QW-III-67B (5FAM-GGAYAAPFKKKA) is based on a related
sequence obtained from an oriented peptide library by Songyang et al. directed at
determining tyrosine kinase specificity.44 The Songyang substrate was phosphorylated with
good efficiency by Abl and was minimally phosphorylated by Src, a close relative of Abl
that shares a similar consensus sequence. Another similar sequence has been shown to have
good efficiency for both Abl and Bcr-Abl.45 Based on these favorable properties and the
good specificity for Abl kinase, peptide QW-III-67B was chosen as the starting peptide for
this work.
Characterization of peptide QW-III-67B degradation in cytosolic lysates
To determine whether the peptide QW-III-67B is degraded by cytosolic peptidases, the
peptide was incubated in a Baf/BCR-ABL cell lysate. After varying times, aliquots were
removed and separated by electrophoresis followed by detection of all fluorescent peptides
(Figure 1A–1C). At time zero, a single peak with a migration time identical to that of the
standard intact peptide QW-III-67B was present. Within one minute, three peaks were seen,
the intact peptide and two peaks with longer migration times. Under these conditions, the
starting peptide possessed a half-life of 1.3 ± 0.4 min in the cytosolic lysate. The average
rate of peptide breakdown in the cell lysate over 5 min was 1.7 ± 0.3 zmol pg−1 s−1 and
approximately 6.2 ± 2.7 % of the intact peptide remained after 5 min. After 30 min, the
initial peak was no longer identified and five additional peaks had formed, all with migration
times slower than the intact peptide. Given the presence of peptidases in a cytosolic lysate, it
was likely that these peaks were proteolytic fragments of the intact starting substrate. In
order to determine the temporal pattern of fragment formation, the percentage of each
fragment with respect to total peptide was plotted as a function of time (Figure 1D). The
initial fragment was generated nearly as fast as the intact peptide was degraded, with an
average initial rate of 1.2 ± 0.1 zmol pg−1 s−1. It is possible that the later appearing
fragments were formed as a consequence of further peptidase action on the first fragment.
Phosphorylated product was not observed since neither ATP nor phosphatase inhibitors were
present in the assay.
To compare the breakdown of QW-III-67B in lysates generated with different cells, the
peptide was incubated in a HeLa cell lysate. During various times, aliquots were removed
and separated by capillary electrophoresis. A peptide-fragment pattern similar to that
observed in the Baf/BCR-ABL lysate was present (Figure 1E). The initial rate of breakdown
in the HeLa cell lysate was 1.3 zmol pg−1 s−1 similar to that in the Baf/BCR-ABL lysate.
Additionally the major fragment that formed over time possessed a migration time identical
to the major peak formed in the Baf/BCR-ABL lysate. This product formed at a rate of 1
zmol pg−1 s−1 nearly identical to result in the Baf/BCR-ABL lysate. Two additional peaks
formed on slower time scales and the migration times of these peaks matched the two
secondary peaks formed in the Baf/BCR-ABL lysate. The pattern and rate of breakdown in
HeLa and Baf/BCR-ABL lysates was very similar despite the difference in species and
tumor type. For this reason, subsequent lysate experiments utilized only the Baf/BCR-ABL
cells.
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Characterization of peptides following lysine replacement
Since trypsin-like proteases are common in cells and favor positively charged residues, the
initial cleavage site was thought to be at one of the lysine residues near the carboxy terminus
of the peptide.46 Ornithine, a lysine analog, possesses a positively charged side chain but
with one less carbon (Figure 2). Replacement of lysine with ornithine has been shown to
limit the ability of trypsin to act on lysine-containing substrates.47 Peptides with ornithine
inserted into the peptide in place of one, two, or all three lysine residues (peptides QW-
III-90A through QW-III-90G in Table 1) were synthesized, purified, and then incubated in
the Baf/BCR-ABL cytosolic lysate for varying times. Aliquots were removed and
electrophoresed to assess the formation of fluorescent fragments. The resulting traces were
very similar to that of the control peptide, with the initial timepoint for each peptide showing
a single peak that migrated at the same time as the intact parent. Subsequent time points
demonstrated the disappearance of the initial peak and the appearance of multiple peaks with
slower migration times, presumably fragment peptides of the lysine-substituted peptides. To
determine the pattern of fragment formation, the fraction of peptide present as each fragment
was plotted as a function of time, with results for each of the seven modified peptides
appearing very similar to that of the starting peptide QW-III-67B (Supplementary Figure
S2). Irrespective of the number or location, ornithine-for-lysine substitution provided only a
modest enhancement in stability relative to that of the starting peptide, with the peptide half-
lives (t1/2) in the lysate ranging from 4.3 to 6.0 min compared to the 1.3 min for the starting
peptide (Table 1).
To determine whether the ornithine-for-lysine-substituted peptides retain the ability to be
phosphorylated by Abl kinase, each modified peptide was incubated with Abl kinase in vitro
and aliquots were removed over time and separated. The relative peak areas of the
phosphorylated and non-phosphorylated peptides were used as a measure of the Abl
substrate efficacy. Half of the ornithine-containing peptides were phosphorylated at a faster
rate than that of the QW-III-67B peptide. When the time for 50% peptide phosphorylation
(t50%P) was measured, three of the double-ornithine peptides and one of the single-ornithine
peptides achieved a 1.7-6X shorter t50%P than that of QW-III-67B. The remaining single and
triple-ornithine peptides were phosphorylated more slowly than QW-III-67B with a 3-4X
greater t50%P. While peptidase resistance was slightly improved and kinase substrate
suitability was acceptable, the ornithine-containing peptides did not possess dramatically
improved proteolytic resistance relative to the starting peptide, suggesting that the lysine
residues might not be the initial site of cleavage.
Identification of the peptide fragments
To identify the primary site of peptide-bond hydrolysis, standards consisting of all possible
fluorescent peptide fragments formed from QW-III-67B were synthesized and characterized
by electrophoresis. Under the electrophoretic conditions used, each peptide fragment
migrated at a unique time and was present as a single major peak. Thus, the fragments
formed and peptide cleavage sites targeted by the cytosolic lysate should be readily
identifiable. The starting peptide, QW-III-67B, was incubated in a cell lysate and after the
reaction was stopped, each of the possible fluorescent peptide standards was sequentially
added to the lysate mixture to identify the lysate peaks. Each peak present in the cytosolic
lysate matched to a fragment peak suggesting that the additional peaks on the
electropherogram were indeed fragments of the original peptide (Figure 1). A 7-residue
fragment (peptide f) generated by cleavage at the proline-phenylalanine bond formed
initially and in the greatest quantity. 3, 4, and 5-residue fragments also formed over time but
with a delay relative to that of the 7-mer. Since the proline-phenylalanine bond appeared to
be the site of initial peptide cleavage, these residues were targeted for modification to
enhance stability.
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Characterization of peptides with proline replacement
The proline and phenylalanine in QW-III-67B were replaced with native and non-native
residues (Figure 2) and peptide stability assessed. Proline has a structure unique to the native
residues in that the backbone nitrogen is linked via a ring to the side chain, creating a bend
in the peptide backbone. Three strategies were attempted to replace the proline with a goal
of diminishing peptidase rather than kinase action: i) an alanine was inserted in place of the
proline to eliminate the bend in the peptide backbone; ii) native residues with a side chain
ring were substituted to maintain a similar side chain character while still eliminating the
backbone bend; and iii) the non-native residue sarcosine (N-methylglycine) was used to
maintain the backbone kink yet eliminate the closed-ring structure.48 Peptides QW-IV-74A
to QW-V-74E (Table 1) were synthesized, purified, incubated in a cytosolic lysate and then
separated by CE to determine whether fluorescent fragments were formed. In each case,
approximately eight fluorescent fragments were seen within 5 min of incubation in the
lysate. Although these fragment peaks grew larger over time, additional peaks were not
observed. To compare the peptidase resistance of these peptides to that of the prior peptides,
the percentage of peptide fragment over time was measured and the t1/2 calculated. The t1/2
of all of the proline substituted peptides was improved relative to that of the starting peptide
QW-III-67B and the ornithine-containing peptides (Table 1). The peptide possessing a
sarcosine displayed the most dramatic increase in stability with a t1/2 of 24.0 min compared
to the 1.3 min of the starting peptide (Figure 3A).
To determine whether the proline-substituted peptides also retained the ability to be
phosphorylated by Abl kinase, each modified peptide was incubated with Abl kinase in vitro
and phosphorylation measured over time. Minimal phosphorylation was observed for each
of the five peptides over the assay period. Based on the measured phosphorylation rate,
t50%P for all of these peptides was estimated to be >105 min or >650-times longer than the
150 min of the starting peptide (Figure 3B). Despite the increased peptidase resistance, the
poor substrate efficacy of the proline-substituted peptides rendered these modifications
unsuitable for the creation of protease-resistant Abl kinase substrates.
Characterization of peptides with phenylalanine replacement
Phenylalanine possesses a bulky hydrophobic side group, and therefore non-native residues
with similar features, including β-(2-naphthyl)-L-alanine and 3-nitrotyrosine, were
substituted in place of phenylalanine (Figure 2). Since both N-methylated and D-amino
acids have been shown to impart stability to inhibitor peptides, D-phenylalanine and (N-
methyl)phenylalanine were also incorporated as replacements for phenylalanine.27, 35, 36, 38
Peptides QW-IV-85B through QW-V-23E (Table 1) were synthesized, purified, and then
incubated in the Baf/BCR-ABL cytosolic lysate for varying times. Aliquots were removed
and electrophoresed to assess the formation of fluorescent fragments. Within 1 min, the β-
(2-naphthyl)-L-alanine-substituted peptide showed the appearance of a second peak in the
electropherogram with a migration time slower than the intact peptide. This second peak
grew larger over the course of the assay, and a much smaller, slower migrating peak first
appeared after 30 min incubation. The intact peptide disappeared between 15 and 30 min. A
similar pattern and time course was also observed for the 3-nitrotyrosine-substituted peptide.
The electropherogram of the lysate-incubated, D-phenylalanine peptide did not show
additional peaks until after 5 min of incubation. Unlike the prior two peptides, 30% of the
D-phenylalanine peptide remained intact at 60 min. The (N-methyl)phenylalanine-
substituted peptide showed results similar to that of the D-phenylalanine-substituted peptide
but had an even slower rate of fragment formation with 70% of the peptide co-migrating
with that of the starting peptide after 60 min (Supplementary Figure S3). At this time, 5
additional peaks were present on the electropherogram of the (N-methyl)phenylalanine-
substituted peptide. To compare cytosolic peptidase resistance among these peptides, the
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amount of intact peptide was plotted as a function of time and t1/2 was calculated. As
expected, the (N-methyl)phenylalanine-substituted peptide showed the most dramatic
increase in lifetime, with a 40-fold increase relative to that of the starting peptide QW-
III-67B (Figure 3A). The D-phenylalanine-substituted peptide was also longer lived with a
30-fold increase in t1/2. The remaining two peptides showed more modest results, with a 4
to 7-fold increase in peptide lifetime (Figure 3A).
The ability of each phenylalanine-modified peptide to be phosphorylated in vitro by Abl
kinase was also assessed as described above. Two of the peptides, the (N-
methyl)phenylalanine- and the 3-nitrotyrosine-substituted peptides, showed minimal
phosphorylation, with t50%P >105 min (Figure 3B). The β-(2-naphthyl)-L-alanine- and the
D-phenylalanine-substituted peptides were phosphorylated at similar rates to the parent
peptide with a t50%P of 190 and 82 min, respectively (Figure 3B).
Design and characterization of an (N-methyl)phenylalanine-substituted lead peptide
The (N-methyl)phenylalanine-substituted peptide QW-IV-85B was the most promising
peptide with respect to peptidase resistance but performed poorly as an Abl substrate.
Placement of an isoleucine in the position immediately upstream of the phosphorylated
tyrosine has been shown to improve Abl phosphorylation efficiency of some substrates, but
can make the peptide more suitable for phosphorylation by Src.4, 44 To improve the
substrate behavior of the (N-methyl)phenylalanine-substituted peptide, the alanine adjacent
to the tyrosine was replaced with an isoleucine. This new peptide (QW-V-48B in Table 1)
was characterized for peptidase resistance as well as Abl- and Src-substrate performance.
After a 3 min incubation in the cytosolic lysate, a small peak in addition to QW-V-48B
appeared. Over a 5 min time, the average rate of breakdown was 0.20 ± 0.03 zmol pg−1 s−1
and 79.6 ± 2.5% remained intact in the lysate. By 10 min, the second peak had increased and
was accompanied by two additional peaks. The t1/2 of this peptide was 19.1 ± 3.3 min or 15-
fold longer than that of the starting peptide yet >2 fold less than that of the peptide without
isoleucine (Table 1, Figure 3A). To determine whether this peptide was a substrate for Src,
the peptide was incubated with various concentrations of Src kinase and the amount of
phosphorylation measured. At all concentrations, no phosphorylation by Src was observed
(Supplementary Figure S4). To determine whether the isoleucine improved Abl-substrate
performance, the QW-V-48B peptide was incubated with Abl kinase and the amount of
phosphorylation measured. Incorporation of the isoleucine decreased the t50%P by >2000-
fold relative to that of the peptide with only the (N-methyl)phenylalanine-substitution
(Figure 3B). The isoleucine peptide also possessed a 3.5X lower t50%P than the original
starting peptide. Based on the combined ability of this peptide to resist degradation, resist
Src phosphorylation yet remain a substrate for Abl, peptide QW-V-48B was chosen for
further characterization and evaluation.
Characterization of the lead peptide QW-V-48B in a cytosolic lysate
Although the lead peptide QW-V-48B possessed a substantially increased lifetime relative to
that of the starting peptide QW-III-67B, QW-V-48B was still degraded into multiple
different fragments over time. In order to understand which residues were the preferred sites
of cleavage, all possible fluorescent fragments were synthesized and characterized by
electrophoresis. Under the electrophoretic conditions used, all of these fragment peptides
were resolved from each other and from the parent peptide. The lead peptide, QW-V-48B,
was incubated in a Baf/BCR-ABL cell lysate and each of the possible fluorescent peptide
standards were sequentially added to the mixture to identify the unknown peaks in the
electropherogram. Each of the peaks present in the cytosolic lysate was matched to a
fragment peak (Figure 4). The first fragment formed was a 5-residue peptide cleaved at the
alanine-alanine bond (peptide t) (Figure 4B,E). The amount of each fragment graphed as a
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function of time (Figure 4D) demonstrated that the 5-mer formed at an initial average rate of
0.11 ± 0.02 zmol pg−1 s−1 and accounted for approximately 50% of all peptide present by 60
min (Figure 4D). Other peptides that formed over time were the 3, 4, and 11-residue
fragments, but they formed on longer time scales relative to that of the 5-mer (Figure 4C).
Significantly, there was no evidence of the 7-mer fragment that would be generated from
cleavage between the proline and (N-methyl)phenylalanine. Thus the substitution of (N-
methyl)phenylalanine for phenylalanine greatly enhanced resistance to proteolysis.
The kinetic parameters of KM and kcat were determined for both peptides in order to
quantitatively compare the ability of the starting peptide and lead peptide to act as substrates
for Abl. Varying concentrations of each peptide were incubated with Abl kinase and the
initial reaction velocity calculated. Peptide QW-V-48B had a lower KM than QW-III-67B
(20 μM compared to 58 μM) and also a higher turnover number, (kcat = 3,000 min−1
compared to 2,100 min−1). The lead peptide QW-V-48B was both a better Abl substrate and
possessed greater peptidase resistance than the starting peptide QW-III-67B.
Characterization of peptides in single HeLa cells
Although use of cytosolic lysates enables facile optimization of substrate peptide properties,
most cellular processes are dramatically altered in this homogenous, diluted environment. In
particular, peptidases located within organelles are expected to be released upon cell lysis.
Thus a peptide in a cell lysate may encounter a different repertoire of peptidases relative to a
peptide in the cytosol of an intact cell and it is important to understand whether the peptide
fragments and fragmentation rates from a lysate faithfully mimic that formed in intact cells.
In order to assess and quantify the peptide fragments generated in single cells, peptide QW-
III-67B was microinjected into a single HeLa cell (24 ± 8 amol, n = 4 cells). HeLa cells
were utilized for single cell studies since they were more easily microinjected than non-
adherent cells and possessed a similar fragmentation profile to that of Baf/BCR-ABL cell
lysates (Figure 1E). After a 5 min incubation, cells were lysed and loaded into an overlying
capillary and the different fluorescent peptides detected and quantified.41 The peptide was
nearly completely metabolized, with only 10 ± 2 % remaining intact (Table 2). Under the
conditions used, the average rate of QW-III-67B degradation was calculated to be 0.7 ± 0.2
zmol pg−1 s−1 assuming a cellular protein concentration of 100 mg/mL and a cell volume of
1 pL.49 Nine different peaks were observed on the electropherogram (Figure 5A), compared
to the six peaks seen in the lysate samples (Figure 1C). The peptide fragment standards were
utilized to identify the source of the peaks obtained from the single cells and each fragment
generated in the single cells co-migrated with a standard fragment (Figure 5A). The most
abundant fragment generated was the 5-mer (peptide h) that amounted to 36 ± 6% of all
peptides. This same 5-mer was also generated in the lysate studies but at approximately half
the amount observed in single cells at 5 min. The 7-mer fragment (peptide f) that was
generated the fastest in the lysate studies was present, but to a lesser extent (5 ± 2 %) in the
intact cells. In single cells, the 4, 6, and 11-residue fragments were also seen at amounts
greater than 10 % (Table 2) while of these, only the 4-mer was seen in the lysate studies
(Figure 1). The 2-mer seen in small amounts in the lysate studies was not seen at all in the
intact cell studies. Although the pattern of peptide fragmentation was similar in single cells
compared to lysates, there were important differences. While the peptide concentration
incubated in the cell lysate was roughly 25-times lower than that loaded into single cells and
the lysate protein was 30-times more dilute than a single cell, the rate of peptide metabolism
in the cell lysate still remained significantly greater than that of peptide in an intact cell over
the same time period. Thus the peptidase activity in cell lysates was considerably greater
than that in the cytosol of an intact cell most likely due to the release of sequestered
peptidases from ruptured organelles in the lysate. A second significant difference is the
predominance of peptide h (representing Ala-Ala bond cleavage) in the single cells relative
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to other peptide fragments suggesting that the Ala-Ala bond may be the dominant cleavage
site in single cells and not the Pro-Phe which dominated in the lysate. No phosphorylated
product was detected or expected since HeLa cells do not express Bcr-Abl.
The lead peptide QW-V-48B was microinjected into a single HeLa cell, incubated for 5 min,
and then the cellular contents were electrophoretically separated. On average, 28 ± 6 amol (n
= 4 cells) of QW-V-48B was loaded into the cells. The peptide was degraded at an average
rate of 0.6 ± 0.1 zmol pg−1 s−1 with 33 ± 14% remaining intact after 5 min (Table 2). Thus
the average rate of metabolism in single cells was similar for the starting and lead peptides.
Five peaks were observed on the electropherogram (Figure 5B) and the migration time of
each of these peaks matched to that of a QW-V-48B fragment standard (Figure 5B, D). The
7-residue fragment representing cleavage between the proline and (N-methyl)phenylalanine
was not present in the single cells. This bond was effectively stabilized by replacement with
a non-native amino acid. However, 4, 5, and 11-residue peptide fragments were present with
the 5-mer (peptide t), representing the Ala-Ala bond cleavage, being the most abundant with
22 ± 10 % present after 5 min. The 2-mer observed in cell lysates (Figure 4C) was absent
from the single cells; however, the single cells possessed a 6-amino acid fragment not
observed in the lysates. As with QW-III-67B, peptide metabolism in the single cell was
similar to that in a lysate but with some key differences. Since the rate of metabolism of
QW-V-48B and QW-III-67B in single cells was nearly identical, replacement of the Pro-Phe
bond did not stabilize the peptide in the single cells. The predominance of peptide h and t for
both QW-III-67B and QW-V-48B in single cells suggests that the Ala-Ala bond is the
preferred location for bond cleavage in the intact cytosol where disruption of the organelles
has not occurred. No phosphorylated product was detected in any single cells.
Conclusions
Identification of the exact cleavage locations within a peptide permitted rational peptide
redesign by placement of non-native residues at hydrolysis sites, resulting in increased
peptide lifetimes in a cytosolic lysate. By contrast, both the starting and lead peptides
showed similar degradation rates in intact cells suggesting that the cell lysate system may
not be a good model for estimating intracellular rates and patterns of peptide proteolysis. It
is likely that different peptidases acted on the substrates in single cells compared to that in
lysates, leading to differences in primary cleavage sites and rates of proteolysis. One caveat
is that only a single time point was sampled for the single cells and formation of the
fragments over time was not determined. Assay of single cells loaded with peptide and
incubated for other times would lead to a more complete picture of peptide fragmentation
and permit further analysis of substrate lifetime in intact cells. A key goal for future work is
the creation of proteolytic resistant intracellular substrates of the Abl kinase.
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Degradation profile of the starting peptide (QW-III-67B) in a cell lysate. (A) –(C)
Electropherograms of the peptide after incubation in the Baf/BCR-ABL lysate for 0 (A), 1
(B), or 30 (C) min. (D) Formation of peptide fragments over time in the Baf/BCR-ABL
lysate. (E) Formation of peptide fragments over time in a HeLa–cell lysate. Shown on the y-
axis is the percentage of peptide present as a fragment. The symbols are defined as: filled
square (peptide a or starting peptide), open square (peptide f), closed triangle (peptide h),
open circle (peptide i), closed circle (peptide j) and open triangle (peptide k). The symbols
and error bars represent the average and standard deviation of the data points. (F) The
uppercase letters are the single amino acid abbreviations for the starting peptide sequence.
The lowercase letters indicate the cleavage locations that generate the indicated peptide
fragments.
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The native residues and the non-native residues that were inserted into the peptide to
stabilize the peptide against hydrolysis.
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Baf/BCR-ABL cytosolic lysate degradation (A) and in vitro phosphorylation (B) of
modified peptides. Filled square (QW-III-67B, starting peptide); open diamond (QW-
IV-74D, sarcosine-substituted peptide); closed circle (QW-IV-85B, (N-
methyl)phenylalanine-substituted peptide); open circle (QW-V-23C, β-(2-naphthyl)-L-
alanine-substituted peptide); open triangle (QW-V-23E, 3-nitro tyrosine-substituted
peptide); and closed triangle (QW-V-48B, isoleucine and N-methylated phenylalanine-
substituted peptide). The symbols and error bars represent the average and standard
deviation of the data points.
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Degradation profile of the lead peptide (QW-V-48B) in a Baf/BCR-ABL cell lysate. (A) –
(C) Electropherograms of the peptide after incubation in the lysate for 0 (A), 1 (B), or 30 (C)
min. (D) Formation of peptide fragments over time. Shown on the y-axis is the percentage of
peptide present as a fragment. The symbols are defined as: filled square (peptide m), open
square (peptide n), closed triangle (peptide t), open circle (peptide u), open triangle (peptide
w). The symbols and error bars represent the average and standard deviation of the data
points. (E) The uppercase letters are the single amino acid abbreviations for the lead peptide
sequence and MPh represents N-methylated phenylalanine. The lowercase letters indicate
the cleavage locations that generate the indicated peptide fragments.
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Degradation of peptides in single HeLa cells. Cells were microinjected with QW-III-67B
(A,C) or the lead peptide QW-V-48B (B,D). (A,B) Electropherogram of a single cell 5 min
after microinjection. The lowercase letters label the peptide fragments as defined in Figures
1F and 3F. (C,D) Identification of fragments formed in single cells. Single cell contents
were loaded into a capillary 5 min after starting or lead peptide microinjection into the cell.
Immediately after loading the cell contents into the capillary, the fragments of the starting
peptide QW-III-67B (C) or lead peptide QW-V-48B (D) were loaded into the capillary. A
voltage was then applied to the capillary to initiate simultaneous electrophoresis of the
cellular contents and fragment standards.
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